Haemostatix, a spinout of Leicester University, has a claimed £20,000 ($31,240) prize from the Royal Society of Chemistry in its Emerging Technologies Competition.
The firm is developing technology which can control bleeding in surgery and trauma, based on a synthetic peptide construct which forms a fibrin-like clot.
Ben Nichols, CEO of Haemostatix, said: “This competition is highly competitive and prestigious so we are delighted to have been awarded first prize. To have the healthcare industry recognise the potential of this new technology is extremely positive and we hope that our compounds will go on to benefit patients in hospitals all over the world.”
